1. Home
  2. PERI vs DSGN Comparison

PERI vs DSGN Comparison

Compare PERI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perion Network Ltd.

PERI

Perion Network Ltd.

HOLD

Current Price

$10.26

Market Cap

412.5M

Sector

Technology

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.22

Market Cap

418.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PERI
DSGN
Founded
1999
2017
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
412.5M
418.1M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
PERI
DSGN
Price
$10.26
$9.22
Analyst Decision
Strong Buy
Buy
Analyst Count
3
1
Target Price
$14.75
$13.00
AVG Volume (30 Days)
401.7K
457.9K
Earning Date
11-12-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$432,361,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$11.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.00
$2.60
52 Week High
$11.79
$9.85

Technical Indicators

Market Signals
Indicator
PERI
DSGN
Relative Strength Index (RSI) 60.74 71.64
Support Level $9.30 $8.21
Resistance Level $9.96 $9.85
Average True Range (ATR) 0.41 0.68
MACD 0.05 0.20
Stochastic Oscillator 54.50 82.97

Price Performance

Historical Comparison
PERI
DSGN

About PERI Perion Network Ltd.

Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: